Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Do molecular diagnostics add to clinical characteristics in selecting patients for gefitinib treatment?

Nature Clinical Practice Oncology volume 5, pages 10–11 (2008)Cite this article

boxed-textCappuzzo F et al. (2007) Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization–positive/phospho-Akt–positive or never smoker patients with advanced non–small-cell lung cancer: the ONCOBELL trial. J Clin Oncol 25: 2248–2255

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Riely GJ et al. (2006) Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin Cancer Res 12: 7232–7241

    Article  CAS  Google Scholar 

  2. Bunn PA Jr. et al. (2006) Biological markers for non-small cell lung cancer patient selection for epidermal growth factor receptor tyrosine kinase inhibitor therapy. Clin Cancer Res 12: 3652–3656

    Article  CAS  Google Scholar 

  3. Pao W et al. (2005) KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib. PLoS Med 2: e17

    Article  Google Scholar 

  4. Shepherd F et al. (2007) Updated molecular analyses of exons 19 and 21 of the epidermal growth factor receptor (EGFR) gene and codons 12 and 13 of the KRAS gene in non-small cell lung cancer (NSCLC) patients treated with erlotinib in National Cancer Institute of Cancer Clinical Trials Group BR.21 [abstract #7571]. Proc Am Soc Clin Oncol 25 (Suppl 18 Part 1)

Download references

Acknowledgements

We thank Gregory Riely, MD PhD for his thoughtful review of the manuscript. The synopsis was written by Helen Jaques, Editorial Assistant, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. YY Janjigian is a Fellow in Medical Oncology and Hematology and VA Miller is a Medical Oncologist in the Department of Medicine at Memorial Sloan–Kettering Cancer Center, New York, NY, USA.,

    Yelena Y Janjigian & Vincent A Miller

Authors
  1. Yelena Y Janjigian
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vincent A Miller
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vincent A Miller.

Ethics declarations

Competing interests

VA Miller is a consultant for Genentech and OSI, and is co-holder of a provisional patent for the Thr790Met EGFR mutation with Molecular MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Janjigian, Y., Miller, V. Do molecular diagnostics add to clinical characteristics in selecting patients for gefitinib treatment?. Nat Rev Clin Oncol 5, 10–11 (2008). https://doi.org/10.1038/ncponc0997

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc0997

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing